Nuclear Medicine
Consultant – Nuclear Medicine9+ Years
Fortis Hospital
Bangalore
Dr. Chandra Teja Reddy Singareddy is a Nuclear Medicine Specialist and Therapeutic Nuclear Medicine Consultant in Bangalore, currently associated with Fortis Hospital, Bannerghatta Road. He specialises in nuclear medicine imaging, molecular imaging, PET-CT investigations and radionuclide-based therapies for selected medical conditions. His clinical interests include thyroid nuclear medicine, cancer imaging, therapeutic nuclear medicine and the use of radioactive tracers to evaluate disease activity and treatment response.
Dr. Chandra Teja Reddy Singareddy holds MBBS, MD in Nuclear Medicine and DM in Therapeutic Nuclear Medicine. He completed his MBBS at Kurnool Medical College in 2016, followed by an MD in Nuclear Medicine at Sri Venkateswara Institute of Medical Sciences, Tirupati, in 2020. He subsequently pursued advanced superspeciality training in Therapeutic Nuclear Medicine at the All India Institute of Medical Sciences, New Delhi. His training combines diagnostic molecular imaging with the medical application of radionuclide-based treatment techniques.
As a Nuclear Medicine Specialist in Bangalore, Dr. Chandra Teja Reddy provides specialist evaluation using diagnostic nuclear medicine techniques such as PET-CT and gamma camera imaging. These investigations use small quantities of radiopharmaceuticals to assess biological processes inside the body. Nuclear medicine imaging may help evaluate selected cancers, thyroid disorders and other conditions that require functional or molecular information beyond conventional anatomical imaging.
Dr. Chandra Teja Reddy Singareddy has a particular clinical and academic interest in therapeutic nuclear medicine, including radioactive iodine treatment for selected thyroid conditions. His professional profile identifies expertise in radioiodine therapy for benign and malignant thyroid disorders. His research also examines the role of pre-therapy and post-therapy iodine scans in differentiated thyroid cancer. Treatment decisions require appropriate patient selection, assessment of thyroid disease and adherence to radiation safety precautions.
His additional clinical interests include nuclear oncology, neuroendocrine tumour imaging, parathyroid localization and selected radionuclide therapies. His professional listing describes experience with Yttrium-90 microsphere therapy for liver tumours. His scientific publications also examine the role of FDG PET-CT, Gallium-68 DOTANOC PET-CT and fluorocholine PET-CT in evaluating different tumours and endocrine abnormalities. These imaging techniques may help specialists assess disease extent, detect certain abnormalities and guide further management.
Dr. Chandra Teja Reddy has contributed to national and international nuclear medicine research. He received the Prof. Ramdas Gold Medal for Best Paper in Nuclear Thyroidology at SNMICON 2022. He has served as Principal Investigator on an ICMR research project involving PET-CT assessment in breast cancer immunotherapy and has contributed to peer-reviewed articles covering thyroid cancer, neuroendocrine tumours, pancreatic masses, renal lesions and molecular imaging findings.
His professional affiliations include the Society of Nuclear Medicine, India, and the Association of Nuclear Medicine Physicians of India. He has also received recognition from Asian and European nuclear medicine boards. At Fortis Hospital Bannerghatta Road, his professional focus includes diagnostic nuclear medicine, molecular imaging and appropriately selected radionuclide therapies, with treatment planning based on clinical indications, imaging results, multidisciplinary recommendations and radiation safety requirements.
Diagnostic nuclear medicine uses radiopharmaceuticals and specialised cameras to examine how organs and tissues function. Dr. Chandra Teja Reddy Singareddy specialises in nuclear medicine imaging and molecular investigations. These techniques may help assess selected cancers, thyroid disorders and other medical conditions where functional imaging provides clinically useful information.
Positron Emission Tomography combined with Computed Tomography provides functional and anatomical information in a single imaging examination. Dr. Chandra Teja Reddy has expertise in PET-CT imaging and related research. The scan may be used for selected cancer investigations and other conditions depending on the tracer, clinical indication and diagnostic requirements.
FDG PET-CT uses a radioactive glucose analogue to identify tissues with increased metabolic activity. Dr. Chandra Teja Reddy has published research involving FDG PET-CT in various cancers. Imaging may assist with staging, treatment response evaluation and detection of selected abnormalities, although interpretation depends on clinical history and other investigations.
Gamma camera imaging detects radiation emitted by specific radiopharmaceuticals to produce information about organ function or disease activity. Dr. Chandra Teja Reddy has documented expertise in diagnostic gamma camera studies. Such examinations may support assessment of thyroid function and other conditions requiring specialised nuclear medicine investigations.
Radioactive iodine therapy uses iodine-131 to treat selected thyroid conditions. Dr. Chandra Teja Reddy has specialist training in therapeutic nuclear medicine and documented expertise in radioiodine treatment. Before treatment, patients undergo assessment of the thyroid diagnosis, relevant medical history and safety considerations, including pregnancy-related precautions and radiation protection requirements.
Radioiodine treatment may be recommended for selected patients with differentiated thyroid cancer, often following thyroid surgery. Dr. Chandra Teja Reddy has specific clinical and research expertise in radioactive iodine therapy for thyroid malignancies. Treatment decisions depend on cancer risk, previous treatment, radioiodine sensitivity and specialist recommendations.
Radioactive iodine can be used to treat certain benign thyroid disorders, particularly selected forms of hyperthyroidism. Dr. Chandra Teja Reddy is listed as having experience with radioiodine therapy for benign thyroid conditions. Patient suitability depends on the diagnosis, thyroid function, previous treatment and relevant medical contraindications.
Iodine-131 whole-body scanning is used in selected patients with differentiated thyroid cancer to identify iodine-avid thyroid tissue or disease. Dr. Chandra Teja Reddy has published research involving diagnostic and post-therapy iodine scans. Results may help specialists assess disease distribution and determine appropriate follow-up management.
Post-therapy radioiodine imaging is performed after selected radioactive iodine treatments to evaluate where the administered iodine has accumulated. Dr. Chandra Teja Reddy has investigated the additional value of post-treatment iodine scans in differentiated thyroid cancer. Findings may assist with subsequent disease assessment and treatment planning.
Nuclear medicine imaging can contribute to cancer staging by identifying selected sites of metabolically active or radiotracer-avid disease. Dr. Chandra Teja Reddy has clinical and academic experience in oncology-related PET-CT imaging. The choice of examination depends on cancer type, disease characteristics and multidisciplinary oncology recommendations.
PET-CT and other molecular imaging examinations may help evaluate treatment response in selected cancers. Dr. Chandra Teja Reddy has undertaken research on PET-CT imaging in breast cancer immunotherapy. Interpretation considers tracer uptake, prior imaging, treatment history and the possibility of inflammatory or treatment-related findings.
Neuroendocrine tumour imaging uses selected molecular tracers to identify tumours expressing relevant biological targets. Dr. Chandra Teja Reddy has contributed to research involving neuroendocrine tumour imaging, including Gallium-68 DOTANOC PET-CT. Such investigations may help assess disease distribution and support multidisciplinary decisions about further treatment.
Gallium-68 DOTANOC PET-CT is a molecular imaging technique used for evaluating selected somatostatin receptor-expressing neuroendocrine tumours. Dr. Chandra Teja Reddy has published research involving this tracer. The examination may assist with tumour localization, staging and assessment for certain targeted radionuclide treatments when clinically appropriate.
Parathyroid adenoma localization helps identify overactive parathyroid tissue in selected patients with primary hyperparathyroidism. Dr. Chandra Teja Reddy has contributed to research involving fluorocholine PET-CT for locating unusual parathyroid adenomas. Imaging findings may help surgeons plan treatment when conventional investigations are inconclusive.
Fluorocholine PET-CT uses a specialised radioactive tracer to examine selected metabolic processes. Dr. Chandra Teja Reddy has published research on its use in detecting parathyroid adenomas at unusual anatomical sites. Clinical use depends on the indication, tracer availability and suitability of the examination.
Yttrium-90 microsphere therapy is a targeted internal radiation treatment used for selected liver tumours. HexaHealth lists it among Dr. Chandra Teja Reddy's therapeutic nuclear medicine interests. Treatment usually requires coordinated assessment involving interventional radiology, nuclear medicine and oncology specialists, and its current availability must be confirmed with the hospital.
MBBS, MD (Nuclear Medicine), DM (Therapeutic Nuclear Medicine)
Diagnostic Nuclear Medicine, Therapeutic Nuclear Medicine, PET-CT Imaging, FDG PET-CT Cancer Imaging, Gamma Camera Imaging, Thyroid Nuclear Medicine Imaging, Radioactive Iodine Therapy, Radioiodine Treatment for Thyroid Cancer, Radioiodine Treatment for Selected Benign Thyroid Disorders, I-131 Whole-Body Scanning, Post-Therapy Radioiodine Imaging, Nuclear Medicine Cancer Staging Assessment
Genuine patient experiences and treatment feedback.
Quick answers to common questions about Dr. Chandra Teja Reddy Singareddy
Dr. Chandra Teja Reddy Singareddy is a Consultant Nuclear Medicine Specialist at Fortis Hospital, Bannerghatta Road, Bangalore. He specialises in diagnostic nuclear medicine, therapeutic nuclear medicine, PET-CT imaging, thyroid nuclear medicine and radionuclide-based treatments for selected diseases.
Dr. Chandra Teja Reddy holds MBBS, MD (Nuclear Medicine) and DM (Therapeutic Nuclear Medicine). He completed MBBS from Kurnool Medical College, MD from SVIMS Tirupati and DM from AIIMS New Delhi.
6 years of experience, while HexaHealth reports over 9 years. The correct overall and specialist experience should be confirmed before publishing a definitive figure.
Dr. Chandra Teja Reddy specialises in nuclear medicine diagnosis and treatment, including selected thyroid diseases, thyroid cancer and conditions requiring molecular imaging. His expertise also includes cancer-related PET-CT investigations and assessment for appropriate radionuclide therapies.
Dr. Chandra Teja Reddy has documented expertise in PET-CT and molecular imaging. PET-CT may help evaluate selected cancers, assess disease activity and monitor treatment response. The appropriate scan depends on the patient's diagnosis and the clinical question being investigated.
Contact us for personalized help or to schedule an appointment.